BACKGROUND: A phase II randomised discontinuation trial assessed @entity14820 ( @entity14820 ), an orally bioavailable inhibitor of @entity4149 kinases including VEGF receptors, MET, and @entity14029 , in a cohort of @entity1 with @entity320 . METHODS: @entity1 received @entity14820 100   mg daily during a 12-week lead-in. @entity1 with @entity66 ( @entity66 ) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to @entity14820 or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS). RESULTS: Seventy-seven @entity1 were enroled (62% cutaneous, 30% uveal, and 8% mucosal). At week 12, the ORR was 5%; 39% of @entity1 had @entity66 . During the lead-in phase, reduction in target lesions from baseline was seen in 55% of evaluable @entity1 overall and in 59% of evaluable @entity1 with @entity2184 . Median PFS after randomisation was 4.1 months with @entity14820 and 2.8 months with placebo (hazard ratio of 0.59; P=0.284). Median PFS from study day 1 was 3.8 months, 6-month PFS was 33%, and median overall survival was 9.4 months. The most common grade 3/4 adverse events were @entity1295 (14%), @entity101 (10%), and @entity490 (8%). One treatment-related @entity204 was reported from @entity298 due to diverticular perforation. CONCLUSIONS: @entity14820 has clinical activity in @entity1 with @entity320 , including @entity2184 . Further clinical investigation is warranted.

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor @entity14820 in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritonitis'] @entity14029 :: ('558', 'Gene') :: ['AXL'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity14820 :: ('MESH:C558660', 'Chemical') :: ['XL184', 'cabozantinib', 'Cabozantinib'] @entity2184 :: ('MESH:C536494', 'Disease') :: ['uveal melanoma'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity320 :: ('MESH:D008545', 'Disease') :: ['metastatic melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['metastatic melanoma']
